Payment overview · 2025
General Payments
$1,137.88
53 reported records · 12 companies
Healthcare provider profile · identity verified
Julian E.C. Mcleod, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · ROCKY MOUNT, NC · NPI 1003898107
Verified facts
What the public records show
CMS Open Payments records show Julian E.C. Mcleod, PA received $1,137.88 in general payments during 2025 across 53 reported records.
Amgen Inc. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $260.47 | 22.9% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $207.92 | 18.3% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $179.54 | 15.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $146.28 | 12.9% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $90.27 | 7.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.67 | 6.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $64.90 | 5.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.42 | 3.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $26.19 | 2.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.66 | 2.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.91 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.65 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,137.88 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $260.47 | 13 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $139.67 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $114.69 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $110.47 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $93.56 | 8 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $90.27 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $72.08 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $52.49 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $51.84 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.63 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $22.36 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $9.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 146 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 113 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
146 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 444 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 89 |
| Lisinopril | Lisinopril | 222 | 63 |
| Metformin Hcl | Metformin Hcl | 203 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 54 |
| Furosemide | Furosemide | 170 | 37 |
| Simvastatin | Simvastatin | 168 | 46 |
| Gabapentin | Gabapentin | 160 | 47 |
| Losartan Potassium | Losartan Potassium | 158 | 45 |
| Farxiga | Dapagliflozin Propanediol | 146 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 31 |
| Omeprazole | Omeprazole | 116 | 34 |
| Jardiance | Empagliflozin | 113 | 26 |
| Potassium Chloride | Potassium Chloride | 110 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 29 |
| Eliquis | Apixaban | 104 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 104 | 30 |
| Meloxicam | Meloxicam | 96 | 22 |
| Montelukast Sodium | Montelukast Sodium | 83 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 27 |
| Metformin Hcl Er | Metformin Hcl | 81 | 28 |
| Allopurinol | Allopurinol | 79 | 23 |
| Rybelsus | Semaglutide | 78 | 14 |
| Ozempic | Semaglutide | 77 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 21 |
| Alprazolam | Alprazolam | 66 | 21 |
| Trazodone Hcl | Trazodone Hcl | 65 | 14 |
| Ezetimibe | Ezetimibe | 62 | 17 |
| Baclofen | Baclofen | 52 | 15 |
| Carvedilol | Carvedilol | 50 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 21 |
| Sertraline Hcl | Sertraline Hcl | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Valsartan | Valsartan | 37 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | 11 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Prednisone | Prednisone | 34 | 22 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 13 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 11 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Kerendia | Finerenone | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Colchicine | Colchicine | 20 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Brilinta | Ticagrelor | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,137.88 · 53 records | Amgen Inc. | AIRSUPRA, CREON, FARXIGA, JARDIANCE, KISUNLA, Korlym, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, OTEZLA, REPATHA, REXULTI, SYNTHROID, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error